Crystagen

peptide · headlineResearch use only

Normalizes thymus-derived peptide signaling pathways

Overview

Crystagen is a thymic-derived peptide bioregulator that modulates immune function, supports thymic repair, and enhances lymphocyte output. It is administered orally and has been shown in Eastern European research to improve immune performance in aging and immunosuppressed individuals.

How it works

Normalizes thymus-derived peptide signaling pathways
Stimulates lymphocyte differentiation and cytokine balance
Restores immune regulatory gene expression in aged individuals

Dosing

1–2 capsules daily for 10–30 days depending on immune status. Repeat 2–3x per year.

Oral2 capsules standardrange 1–3 capsules· Daily

Caution: Administered at 100–200 μg per day in studies. Clinical use is not authorized.

Cycling

Typical course: 10–30 days of daily dosing. Repeat up to 2–3x per year for immune maintenance.

Side effects

Stacking & combinations

With: Thymosin Alpha-1
Benefit: Synergistic T-cell activation and immune rejuvenation with Thymosin Alpha-1

With: Thymogen
Benefit: Immune modulation enhanced when paired with Thymogen

Lifestyle support

Diet: Balanced nutrient-dense diet. Stay hydrated.
Sleep: Adequate sleep (7–9 hours). Manage stress.
Timing: Consistent daily dosing.
Exercise: Regular physical activity.

Research studies

Studies summarized for educational purposes only. Inclusion does not imply human use; referenced research was conducted in vitro, in animal models, or in regulated clinical trials.

Research study

Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process

Chervyakova NA, Linkova NS, Chalisova NI, Koncevaya EA, Trofimova SV, Khavinson VKh Advances in Gerontology (Adv Gerontol), 2014;27(1):224-228 View source ↗

Scientific findings

Using an organotypic tissue-culture model of spleen from young and old animals, the authors compared the immunotropic activity of the short peptides Vilon, Thymogen, Crystagen, and R-1, assessing effects on cell proliferation, apoptosis, and differentiation of immune-cell subpopulations. Crystagen was found to activate B-lymphocytes of the immune system, but, in contrast to peptides such as Vilon and R-1 (which stimulate T-helpers and cell renewal), Crystagen did not induce cellular renewal/proliferation in the aging spleen. The work frames distinct, peptide-specific mechanisms of immunoprotection during splenic ageing.

Plain English

Researchers grew spleen tissue from young and old animals and tested several short peptides, including Crystagen, to see how each supports the aging immune system. Crystagen appeared to switch on B-cells (the antibody-producing immune cells) but, unlike some of the other peptides tested, did not help the old spleen generate new cells. This is early-stage laboratory (tissue-culture) research from the Khavinson group, not a human clinical trial. It is the only dedicated Crystagen study indexed on PubMed.

Verified citations

1 · PubMed-checked

Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process.preclinicalPMID 28976144 ↗

Reconstitution

Not applicable — this compound is oral. No vial reconstitution needed.

Refrigerate at 4 °C (39.2 °F); stable for approximately 30 days

Chemistry & PK

Sequence: Ala-Glu-Asp-Gly
Half Life: Not published; effects persist through gene expression regulation
Degradation: Metabolized via standard proteolytic peptide pathways
Molecular Weight: 467.57
Molecular Formula: C23H37N5O6
Tissue Specificity: Thymus, lymph nodes, and peripheral immune cells

Bioavailability

Oral: Formulated for oral delivery via capsule; effective for gene modulation at low doses
Subq: Not applicable to this compound

Storage & handling

Lyophilized: refrigerate at 4 °C (39.2 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 4 °C (39.2 °F) for up to 30 days
Reconstituted: Refrigerate at 4 °C (39.2 °F); stable for approximately 30 days

Used for

No condition evidence rows yet.

Legal / compounding

Research use only

EU: Not Approved
FDA: Not Approved
Canada: Not Approved
Australia: Not Approved

Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.